Oral Mucositis Clinical Trial
Official title:
A Randomized, Double Blind, Controlled, Multi-center, Phase III Study to Assess Efficacy of Low Level Diode Laser (100 MW, 658 Nm), in the Prevention and Treatment of Radiochemotherapy-induced Mucositis in Head and Neck Cancer.
The purpose of the study is to assess in a randomized, double blind, controlled, multi-center, phase III study, the efficacy of low level diode laser (100 MW, 658 Nm), in the prevention and treatment of radiochemotherapy-induced mucositis for stage III and IV head and neck carcinomas.
This is a Phase III randomized, double-blind, multicenter study, with two groups of patients
receiving radiotherapy and concomitant chemotherapy.
The patients will be randomized as follows: Arm A = patients will receive a preventive and
curative treatment by low-energy laser, and arm B = a control group treated with standard
local treatments and a placebo laser (laser nonfunctional).
Randomization will be balanced in a ratio 1: 1 and stratified by the investigator site.
Assessments of mucositis, nutritional status, tolerance of the laser and pain will be
performed throughout the treatment, once a week, by an investigator unaware of the patients
treatment arm. The locoregional control will be evaluated every 3 months during the first
year, then every 6 months up to 5 years. In case of progression, treatments undertaken and
their results should be reported.
Radiotherapy: All patients will be treated with conformal radiotherapy with or without IMRT.
The dose should be adapted to the treatment indication (exclusive or postoperative) and the
histological findings in case of tumoral resection.
The radiotherapy will be prescribed in accordance with the recommendations of the ICRU 50
report. The dose delivered will always be 2 Gy per day 5 times a week. All beams will be
treated in each session. A radiological audit will be conducted for each beam treated by
photons in the first session and at least once a week.
Chemotherapy:
Several chemotherapies concomitant to radiotherapy are possible:
- a combination of 5-FU and Cisplatin
- a combination of 5-FU and Carboplatin
- Cisplatin alone
- Cetuximab alone
Dental care: All patients (except edentulous) will be seen in odontostomatology consultation
prior to the treatment for dental care if necessary or potential production of fluorinated
gutters During the treatment, all patients will receive oral care
The dosimetric study will concern the cross section, the frontal and sagittal planes through
the axis of the lateral beams.
Arm A : laser low-level energy functional The material used will be a diode laser of 100 mW,
with a wavelength of 658 nm. Application will be made after each radiotherapy session in an
adapted room (low light intensity, possibility of ENT examination) on all grades superior or
equal to 2 stomatitis injuries. The application is painless, athermal, odorless and
completely silent. The patient will wear glasses for retinal protection. The operator will
also wear glasses for his protection but allowing nevertheless the view of the beams and its
limits.
The tumor areas macroscopically invaded will be excluded from the areas application.
The energetic dose delivered will be 4 J/cm2. The duration of the treatment for one will be
determined by a corresponding abacus : [t(s) = energy (J/cm2) x surface (cm2) / puissance
(W)]. The overall duration will be a few minutes varying depending on the surface to be
treated The usual dental care will be prescribed when required.
Arm B : laser low-level energy nonfunctional The procedure is identical to the one used in
arm A but the laser will not be functional. The period of application will be around one
minute. All applications will be performed by one single operator by center. The results will
be assessed once a week by another physician (or nurse specifically trained) in each center,
unaware of whether the patients had laser sessions or not, in order to respect the
"blinding". The assessment will be detailed on a specifique sheet, specifying the degree of
mucositis (WHO), the level of pain, body weight , type of feeding , any analgesic treatment
taken by the patient, quality of life specific questionnaire, and the possible end of
treatment or therapeutic modifications (number of cycles of chemotherapy, dosage).
The laser should be started as soon as a grade 2 mucositis (WHO) is observed and will be
continued throughout the radio-chemotherapy until improvement of the mucositis (grade <2).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02229136 -
Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus
|
Phase 2 | |
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Enrolling by invitation |
NCT02662374 -
Oral Hygiene Regimen in Patients on HCT
|
Phase 4 | |
Completed |
NCT00938080 -
Study to Assess Safety and Tolerability of AG013 in Oral Mucositis in Subjects Receiving Induction Chemotherapy for the Treatment of Cancers of the Head and Neck
|
Phase 1 | |
Completed |
NCT00756951 -
Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT00701688 -
Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1 | |
Not yet recruiting |
NCT05059613 -
Thalidomide With or Without Probiotics in Radioactive Oral Mucositis
|
N/A | |
Completed |
NCT04440930 -
White Tea for Prevention of Chemotherapy Induced Mucositis
|
N/A | |
Completed |
NCT05705622 -
The Effect of Nursing Education on Oral Mucositis in Bone Marrow Transplant Patients
|
N/A | |
Completed |
NCT02399228 -
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis
|
Phase 2 | |
Withdrawn |
NCT02589860 -
Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
|
||
Enrolling by invitation |
NCT06122636 -
Efficacy of a Probiotic and Microbiological Analysis on Oral Complications Induced by Antineoplastic Therapies in Patients With HNC
|
N/A | |
Completed |
NCT03689712 -
ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients
|
Phase 3 | |
Terminated |
NCT02539342 -
Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy
|
Phase 3 | |
Completed |
NCT02555501 -
Oral Mucositis and Laser Therapy Associated With Photodynamic Therapy
|
Phase 3 | |
Completed |
NCT01789658 -
Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT00790322 -
Efficacy and Safety Study of SBG vs Placebo in Head and Neck Cancer Patients Undergoing Radiation Therapy
|
Phase 3 | |
Recruiting |
NCT00549952 -
Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients
|
N/A | |
Completed |
NCT00289003 -
The Protective Effect of Soluble Beta-1,3/1,6-Glucan Compared to Placebo in Oral Mucositis in Head and Neck Cancer Patients
|
Phase 2 | |
Completed |
NCT05635929 -
Oral Mucositis and Quality of Life With a Mucosa Topical Composition in Head & Neck Cancer Patients.
|
N/A |